Literature DB >> 14648019

Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.

U Berger1, G Engelich, A Reiter, A Hochhaus, R Hehlmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14648019     DOI： 10.1007/s00277-003-0807-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

Review 1.  [Molecular target structures in oncology].

Authors:  K Spiekermann; W Hiddemann
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

Review 2.  [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments].

Authors:  C Jochims; U Mazitschek; D Jäger; H Goldschmidt
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

3.  Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.

Authors:  Ibrahim C Haznedaroğlu
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

4.  [Analysis of correlation between plasma trough level and response of generic imatinib in the treatment of Chinese patients with chronic myeloid leukemia].

Authors:  J H You; J Chen; L Zhou; S H Du; H Y Lu; S J Sun; J M Li; Z X Shen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.